Zacks: Brokerages Expect Trevena Inc (TRVN) Will Post Earnings of -$0.09 Per Share

Equities analysts forecast that Trevena Inc (NASDAQ:TRVN) will announce ($0.09) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Trevena’s earnings. Trevena posted earnings per share of ($0.13) in the same quarter last year, which indicates a positive year-over-year growth rate of 30.8%. The company is expected to announce its next earnings report on Thursday, August 1st.

On average, analysts expect that Trevena will report full year earnings of ($0.37) per share for the current year. For the next fiscal year, analysts expect that the firm will report earnings of ($0.23) per share. Zacks’ EPS calculations are a mean average based on a survey of research firms that that provide coverage for Trevena.

Trevena (NASDAQ:TRVN) last released its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.02.

A number of research analysts have recently issued reports on the company. Zacks Investment Research lowered Trevena from a “buy” rating to a “hold” rating in a report on Wednesday, May 15th. ValuEngine lowered Trevena from a “hold” rating to a “sell” rating in a report on Friday, May 3rd. Finally, HC Wainwright reissued a “hold” rating and issued a $1.25 target price on shares of Trevena in a report on Thursday, March 14th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $4.69.

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Trevena by 29.2% in the third quarter. Vanguard Group Inc. now owns 2,618,634 shares of the biopharmaceutical company’s stock valued at $5,552,000 after buying an additional 592,152 shares in the last quarter. Vanguard Group Inc boosted its stake in shares of Trevena by 29.2% in the third quarter. Vanguard Group Inc now owns 2,618,634 shares of the biopharmaceutical company’s stock valued at $5,552,000 after buying an additional 592,152 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Trevena by 38.8% in the first quarter. BlackRock Inc. now owns 2,597,930 shares of the biopharmaceutical company’s stock valued at $4,052,000 after buying an additional 725,717 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Trevena by 84.2% in the first quarter. Renaissance Technologies LLC now owns 1,284,038 shares of the biopharmaceutical company’s stock valued at $2,003,000 after buying an additional 587,100 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Trevena by 17.5% in the third quarter. JPMorgan Chase & Co. now owns 541,099 shares of the biopharmaceutical company’s stock valued at $1,147,000 after buying an additional 80,437 shares in the last quarter. Hedge funds and other institutional investors own 25.63% of the company’s stock.

Shares of NASDAQ:TRVN traded up $0.05 during trading on Friday, reaching $1.22. The company had a trading volume of 852,902 shares, compared to its average volume of 2,821,992. The firm has a market cap of $112.67 million, a P/E ratio of -2.90 and a beta of 2.55. The company has a current ratio of 3.58, a quick ratio of 3.58 and a debt-to-equity ratio of 0.18. Trevena has a fifty-two week low of $0.38 and a fifty-two week high of $3.58.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.

Featured Story: Insider Trading

Get a free copy of the Zacks research report on Trevena (TRVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.